Details for New Drug Application (NDA): 214739
✉ Email this page to a colleague
The generic ingredient in BENDAMUSTINE HYDROCHLORIDE is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
Summary for 214739
Tradename: | BENDAMUSTINE HYDROCHLORIDE |
Applicant: | Eugia Pharma |
Ingredient: | bendamustine hydrochloride |
Patents: | 0 |
Pharmacology for NDA: 214739
Mechanism of Action | Alkylating Activity |
Medical Subject Heading (MeSH) Categories for 214739
Suppliers and Packaging for NDA: 214739
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | POWDER;INTRAVENOUS | 214739 | ANDA | Eugia US LLC | 55150-391 | 55150-391-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-391-01) / 5 mL in 1 VIAL, SINGLE-DOSE |
BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | POWDER;INTRAVENOUS | 214739 | ANDA | Eugia US LLC | 55150-392 | 55150-392-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-392-01) / 20 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 25MG/VIAL | ||||
Approval Date: | Jun 5, 2023 | TE: | AP | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 100MG/VIAL | ||||
Approval Date: | Jun 5, 2023 | TE: | AP | RLD: | No |
Complete Access Available with Subscription